Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT01680341
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 272 participants
- Sponsor
- Registry
-
NCT01680341 -
2012-000373-23
-
- Other papers using this trial's data
- Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial
- TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Germany, Malaysia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01680341. Randomized; no masking; primary purpose treatment. Start 2012-08-31 (actual); primary completion 2013-08-22 (actual). Results posted on 2015-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
- Acronym
- BOOST®
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- insulin degludec/insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01680341- Content hash
bdd2abba908791a8050e6f357798565ea2859ff46db22ed521a250962f646921